Top

Published in:

01-06-2000

2-Methoxyestradiol: an Endogenous Antiangiogenic and Antiproliferative Drug Candidate

Authors: Victor S. Pribluda, Edward R. Gubish, Edward R. Gubish, Theresa M. LaVallee, Anthony Treston, Glenn M. Swartz, Shawn J. Green

Published in: Cancer and Metastasis Reviews | Issue 1-2/2000

Title: 2-Methoxyestradiol: an Endogenous Antiangiogenic and Antiproliferative Drug Candidate
Authors: Victor S. Pribluda
Edward R. Gubish
Edward R. Gubish
Theresa M. LaVallee
Anthony Treston
Glenn M. Swartz
Shawn J. Green
Publication date: 01-06-2000
Publisher: Kluwer Academic Publishers
Published in: Cancer and Metastasis Reviews / Issue 1-2/2000
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1023/A:1026543018478

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 1-2/2000

Endothelial Cells of Tumor Vessels: Abnormal but not Absent

An Inducible Melanoma Model Implicates a Role for RAS in Tumor Maintenance and Angiogenesis

Antiangiogenic Chemotherapeutic Agents

HIF-1: Using Two Hands to Flip the Angiogenic Switch

Preclinical MRI Experience in Imaging Angiogenesis

Tek/Tie2 Signaling: New and Old Partners

Keynote webinar | Spotlight on antibody–drug conjugates in cancer